Clinical Pharmacokinetics and Pharmacodynamics of Repaglinide
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 41 (7) , 471-483
- https://doi.org/10.2165/00003088-200241070-00002
Abstract
Repaglinide is a novel, fast-acting prandial oral hypoglycaemic agent developed for the treatment of patients with type 2 diabetes whose disease cannot be controlled by diet and exercise alone....Keywords
This publication has 34 references indexed in Scilit:
- Meglitinide Analogues in the Treatment of Type 2 Diabetes MellitusDrugs & Aging, 2000
- Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.Diabetes Care, 2000
- Single‐Dose Pharmacokinetics of Repaglinide in Subjects with Chronic Liver DiseaseThe Journal of Clinical Pharmacology, 2000
- The Human Hepatic Cytochromes P450 Involved in Drug MetabolismCritical Reviews in Toxicology, 1992
- Oral Hypoglycemic AgentsNew England Journal of Medicine, 1989
- Protein Binding Drug Displacement InteractionsClinical Pharmacokinetics, 1989
- Sulphonylurea Antidiabetic DrugsDrugs, 1989
- Abnormal Patterns of Insulin Secretion in Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1988
- Protein Binding and Drug ClearanceClinical Pharmacokinetics, 1984
- Clinical Pharmacokinetics of DigoxinClinical Pharmacokinetics, 1977